Physician profile
Sheena Simon
NPI 1477073161
$1,218.11
in general payments reported to CMS, 2019-2025
23 companies · $45.73 in 2025
The $45.73 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $227 · 2021: $456 · 2022: $178 · 2023: $296 · 2024: $15.52 · 2025: $45.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $298.93 | 2021-2023 | Xarelto |
| Dexcom, INC. | $124.99 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $81.96 | 2020-2023 | Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.27 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $64.82 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.07 | 2020-2021 | |
| Vifor Pharma, INC. | $59.16 | 2022 | |
| Novo Nordisk INC | $52.11 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $50.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.67 | 2020 | |
| Shionogi INC | $42.62 | 2021-2023 | Fetroja |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.43 | 2023 | Lifevest |
| Portola Pharmaceuticals, LLC | $33.54 | 2020 | |
| Sequel Med Tech, LLC | $30.56 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.28 | 2021 | |
| Pfizer INC. | $24.04 | 2022 | |
| Astellas Pharma US INC | $21.31 | 2022 | |
| Fisher & Paykel Healthcare INC | $17.83 | 2023 | Fisher & Paykel Healthcare |
| Kyowa Kirin, INC. | $15.17 | 2025 | |
| Pharmacosmos Therapeutics INC. | $13.62 | 2020 | |
| Smith+Nephew, INC. | $11.84 | 2021 | |
| Inari Medical, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.